Tiletamine Stats & Data

Evidence-informed harm reduction points and context: (1) Commercial veterinary products (Telazol/Zoletil) contain equimolar zolazepam with tiletamine. After reconstitution, Telazol solution is strongly acidic (pH ≈2.2–2.8), which helps explain reports of intense nasal burn and potential injection-site irritation; this also means sterile, isotonic preparation and low-volume IM administration reduce local irritation. (2) Clean, pure tiletamine HCl (without zolazepam) has circulated on the grey market; user reports consistently describe substantially higher potency than ketamine by weight and a harsher hangover. (3) Numerous community reports describe coarse tremor, disequilibrium, and lingering neurologic symptoms after repeated dosing over hours–days; spacing sessions and avoiding redosing during the active/offset phase is prudent. (4) Dissociative powders are frequently mis-sold or adulterated; drug checking services routinely find dissociatives sold as other drugs (and vice versa), so reagent tests are insufficient to confirm identity and submitting samples for laboratory GC/MS where available is advised. (5) There is little human pharmacokinetic data for tiletamine; extrapolating animal or vet-product data directly to human non-medical use is unreliable. (6) Reagent reference data for tiletamine are scarce/inconsistent; color tests may be misleading, reinforcing the value of professional analysis. (7) If using any veterinary formulation, account for zolazepam: additive sedation and paradoxical interactions with alcohol and GABAergic drugs are possible and can prolong recovery. (8) As with other dissociatives, avoid combining with CNS depressants (alcohol, opioids, benzos) due to increased risk of loss of airway reflexes, emesis with aspiration, and blackouts.